Figure 1. Reasons for not progressing to second line chemotherapy.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website http://www.wjon.org |
Original Article
Volume 3, Number 6, December 2012, pages 264-270
Maintenance Chemotherapy Use for Advanced Non-Small Cell Lung Cancer in an Australian Cancer Centre
Figures
Tables
| Demographics | Number | Percentage |
|---|---|---|
| Age | ||
| < 61 | 25 | 24 |
| 61 - 74 | 44 | 42 |
| > 75 | 36 | 34 |
| Gender | ||
| Male | 65 | 62 |
| Female | 40 | 38 |
| Histology | ||
| Adenocarcinoma | 44 | 42 |
| Squamous cell carcinoma | 15 | 14 |
| Large cell carcinoma | 23 | 22 |
| Unknown | 23 | 22 |
| CarboGem | Gemcitabine | Abigail | Carbotaxel | Gefitinib | UK |
|---|---|---|---|---|---|
| Breakdown of first line chemotherapy regimes. | |||||
| 94 | 5 | 2 | 2 | 1 | 1 |
| Breakdown of second line chemotherapy regimes | |||||
|---|---|---|---|---|---|
| Pemtrexed | Gefitinib | Vandetanib | Erlotinib | Docetaxel | Vinorelbine |
| Breakdown of second line chemotherapy regimes. | |||||
| 11 | 4 | 3 | 2 | 2 | 1 |